Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.68 |
| ▸ | STK16 | O75716 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | YES1 | P07947 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | BCR | P11274 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644215 | 0.93 | AURKB (0.62) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL13594948 | 0.92 | AURKB (0.61) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL647050 | 0.92 | PLK4 (0.61) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL645848 | 0.91 | BTK (0.70) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL14547460 | 0.90 | BTK (0.69) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL2612677 | 0.88 | BTK (0.67) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL644606 | 0.88 | PLK4 (0.69) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL646253 | 0.88 | FYN (0.71) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL13255659 | 0.87 | BTK (0.65) | BTKAURKBPLK4CHEK1AURKA | |
| SCHEMBL646306 | 0.86 | PLK4 (0.71) | BTKAURKBPLK4CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2133349-B1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | XDH, F7, CYP4X1 | BTK 1231/4885AURKB 2321/4885PLK4 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.